Verastem registers open-label extension study for avutometinib-defactinib in LGSOC
New trial gives France-based RAMP-201 participants continued access to the combination after study completion.
Verastem's sole registry update this week is a new open-label extension study for its LGSOC combination therapy.
- Verastem posted a new phase 2 study, "Open-Label Extension Study to Provide Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)" (NCT07747506), status not yet recruiting. The study lets participants with recurrent low-grade serous ovarian cancer who have completed the VS-6766-201(RAMP-201) study continue receiving avutometinib in combination with defactinib without interruption.1 Only patients transferring directly from RAMP-201 can enroll, so no new patients will be added.1 Enrollment is estimated at 2 participants1, with sites in Lyon and Paris, France, and a start estimated for 2026-08-031.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.